Wplyw iniekcji dimeru lizozymu na wyniki dowymieniowego leczenia ostrych zapalen gruczolu mlekowego u krow

• Autorzy: Malinowski E , Niewitecki W. , Nadolny M. , Lassa H. , Smulski S.

Warianty tytułu

EN

Effect of lysozyme dimer injections on results of intramammary treatment of acute mastitis in cows

• Języki publikacji: PL

Abstrakty

EN

The purpose of the field trials was to establish the efficacy of the acute clinical mastitis treatment with antibiotics in connection with an i.v. injection of an immunomodulator (lysozyme dimer). The trials were conducted on 164 cows (190 sick quarters) divided into 4 groups (8 subgroups) after diagnosis was carried out and milk samples were taken. Four antibiotic products (containing: 1/ Amoxycillin + Clavulanic acid + Prednisolone, 2/ Lincomycin + Neomycin + Prednisolone, 3/ Neomycin + Penicillin G + Novobiocin + Streptomycin + Prednisolone, 4/ Penicillin + Neomycin) were given intramammary infusions at doses recommended by manufacturers with or without (control subgroups) one i.v. injection of lysozyme dimer at a dose of 10 µg/kg b.w. (experimental subgroups). Examinations checking results (clinical, bacteriological, SCC) were conducted on the 7th, 14th, and 21st days after treatment. The criteria of recovery were: regression of clinical signs in the udder, normal appearance of milk, decline of bacteria in milk, decrease of SCC. The recovery rates were 74.1% (1), 53.8% (2), 43.5% (3) and 50.0% of the quarters (4) in control subgroups versus 80.0%, 56.0%, 65.2% and 57.1% of quarters, respectively, in experimental subgroups. An average recovery of 56.3% of the quarters treated with intramammary infusions of antibiotic products and 64.9% of the quarters treated with the same antibiotics connected with the single injection of lysozyme dimer (p = 0.11). The average recovery rate among control cows was 56.1% vs. 65.8% among experimental cows (p = 0.1). The injection of the immunomodulator resulted in an increase of recoveries in acute mastitis cases caused by Str. uberis (from 28.3% to 76.9%), CNS (from 68.7% to 90.9%), E. coli (from 16.7% to 63.3%, and A. pyogenes (from 0% to 16.7%) or Staph. aureus (from 0% to 40%). In conclusion, the intramammary antibiotic products at the recommended doses are efficient enough in clinical mastitis cases caused by Str. agalactiae and CNS, poorly efficient in cases caused by E. coli and Str. uberis and not at all in cases caused by Staph. aureus and A. pyogenes. One i.v. injection of lysozyme dimer increases the efficacy of intramammary antibiotic treatment of acute forms of mastitis caused by CNS, Str. dyagalactiae, Str. uberis, E. coli, and even Staph. aureus or Arcanobacterium pyogenes.

Słowa kluczowe

PL

bydlo; dimer lizozymu; krowy mleczne; zapalenie gruczolu mlekowego; skutecznosc; podawanie dowymieniowe; leczenie; choroby zwierzat; ostre zapalenie gruczolu mlekowego

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2006
• Tom: 62
• Numer: 12
• Opis fizyczny: s.1395-1399,rys.,tab.,bibliogr.

Twórcy

autor

Malinowski E

• Panstwowy Instytut Weterynaryjny - Panstwowy Instytut Badawczy, Oddzial w Bydgoszczy, Al.Powstancow Wlkp.10, 85-090 Bydgoszcz

autor

Niewitecki W.

autor

Nadolny M.

autor

Lassa H.

autor

Smulski S.

Bibliografia

• 1.Burton J. L., Erskine R. J.: Immunity and mastitis. Some new ideas for an old disease. Vet. Clin. North. Am. Food Anim. Pract. 2003, 19, 1-45.
• 2.Constable P. D., Morin D. E.: Use of antimicrobial susceptibility testing of bacterial pathogens isolated from the milk of dairy cows with clinical mastitis to predict response to treatment with cephapirin and oxytetracycline. J. Am. Vet. Med. Assoc. 2002, 221, 103-108.
• 3.Donlan R. M.: Role of biofilms in antimicrobial resistance. A. S. A. I. O. J. 2000, 46, 47-52.
• 4.Erskine R. J., Bartlett P. C., VanLente J. L., Phipps C. R.: Efficacy of systemic ceftiofur as a therapy for severe clinical mastitis in dairy cattle. J. Dairy Sci. 2002, 85, 2571-2575.
• 5.Gruet P., Maincent P., Berthelot X., Kaltsatos V.: Bovine mastitis and intramammary drug delivery: review and perspectives. Adv. Drug Deliv. Rev. 2001, 50, 245-259.
• 6.Hillerton J. E., Kliem K. E.: Effective treatment of Streptococcus uberis clinical mastitis to minimize the use of antibiotics. J. Dairy Sci. 2002, 85, 1009-1014.
• 7.Hoe F. S., Ruegg P. L.: Relationship between antimicrobial susceptibility of clinical mastitis pathogens and treatment outcome in cows. J. Am. Vet. Med. Assoc. 2005, 227, 1461-1468.
• 8.Kiczka W.: Od monomeru do dimeru lizozymu. Życie Wet. 1994, 69, 131-136.
• 9.Malinowski E., Kłossowska A., Szalbierz M., Markiewicz H.: Skuteczność leczenia klinicznych postaci mastitis przy zastosowaniu niektórych preparatów i połączeñ antybiotyków z kwasem acetylosalicylowym i chlormetyną. Medycyna Wet. 1993, 49, 354-356.
• 10.Malinowski E., Dudko P., Kłossowska A., Markiewicz H., Szalbierz M., Branicki T., KuŸma R., Janicki Cz.: Efektywność Lydium-KLP w leczeniu mastitis subclinica. Medycyna Wet. 1995, 51, 156-159.
• 11.Malinowski E., Kłossowska A., Niewitecki W., Kaczmarowski M.: Combined method of acute and chronic mastitis treatment with the use of lysozyme dimer and antibiotics. Proc. IDF Inter. Symp. Immunol. Ruminant Mammary Gland. Stresa, Italy 2000, s. 376-378.
• 12.Malinowski E., Kłossowska A.: Diagnostyka zakażeñ i zapaleñ wymienia. Wyd. PIWet. Puławy 2002, s. 5-96.
• 13.Malinowski E.: Trials for an improvement of the efficacy of cows clinical mastitis treatment a review. Achievements and Prospects of Ruminant Medicine. Puławy 2005, 477-489.
• 14.McDougal S.: Intramammary treatment of clinical mastitis of dairy cows with a combination of lincomycin and neomycin, or penicillin and dihydrostreptomycin. N. Z. Vet. J. 2003, 51, 11-116.
• 15.Mehrzad J., Duchateau L., Burvenich C.: Influence of resident milk neutrophils chemiluminescence and viability and severity of bovine coliform mastitis. Mastitis in dairy production. Wageningen Academic Publishers. 2005, 178-184.
• 16.Melchior M. B., Fink-Gremmels J., Gaastra W.: In vitro susceptibility of biofilm growing Staphylococcus aureus isolated for 10 antibiotics. Mastitis in dairy production. Wageningen Academic Publishers 2005, 302-306.
• 17.Milne M. H., Biggs A. M., Barrett D. C., Young F. J., Doherty S., Innocent S. T., Fitzpatrick J. L.: Treatment of persistent intramammary infections with Streptococcus uberis in dairy cows. Vet. Rec. 2005, 157, 245-250.
• 18.Obmiñska-Mrukowicz B., Szczypka M., Gaweda B.: Modulation of murine macrophages and T lymphocytes by lysozyme dimer. Pol. J. Vet. Sci. 2002, 5, 237-241.
• 19.Oliver S. P., Almeida R. A., Gillespie B. E., Headrick S. J., Dowlen H. H., Johnson D. L., Lamar K. C., Chester S. T., Moseley W. M.: Extended ceftiofur therapy for treatment of experimentally-induced Streptococcus uberis mastitis in lactating dairy cattle. J. Dairy Sci. 2004, 87, 3322-3329.
• 20.Owens W. E., Ray C. H., Watt J. L., Yancey R. J.: Comparison of success of antibiotic therapy during lactation and results of antimicrobial susceptibility tests for bovine mastitis. J. Dairy Sci. 1997, 80, 313-317.
• 21.Owens W. E., Nickerson S. C., Ray C. H.: Efficacy of parenterally or intramammarily administered tilmicosin or ceftiofur against Staphylococcus aureus mastitis during lactation. J. Dairy Sci. 1999, 82, 645-647.
• 22.Paape M. J., Bannerman D. D., Zhao X., Lee J. W.: The bovine neutrophil: Structure and function in blood and milk. Vet. Res. 2003, 34, 597-627.
• 23.Philpot W.: Strategies for handling mastitis problem herds. Achievements and prospects of ruminant medicine. Puławy 2005, 22-30.
• 24.Prees du J. H.: Bovine mastitis therapy and why it fails. J. S. Afr. Vet. Assoc. 2000, 71, 201-208(3).
• 25.Pyörälä S.: New strategies to prevent mastitis. Reprod. Dom. Anim. 2002, 37, 211-216.
• 26.Riollet C., Reinard P., Poutrel B.: Cells and cytokines in inflammatory secretions of bovine mammary gland. Adv. Axp. Med. Biol. 2000, 480, 247-258.
• 27.Roberson J. R., Warnick L. D., Moore G.: Mild to moderate clinical mastitis: efficacy of intramammary amoxicillin, frequent milk-out, a combined intramammary amoxicillin, and frequent milk-out treatment versus no treatment. J. Dairy Sci. 2004, 87, 583-592.
• 28.Rymuszka A., Studnicka M., Siwicki., Sierosławska A., Bownik A.: The immunomodulatory effects of the dimer of lysozyme (KLP-602) in carp (Ciprinus carpio L.) in vivo study. Ecotoxicol. Environ. Saf. 2005, 61, 121-127.
• 29.Sandholm M., Kaartinen L., Pyörälä S.: Bovine mastitis why does antibiotic therapy not always work? An overview. J. Vet. Pharmacol. Ther. 1990, 13, 248- -260.
• 30.Saran A., Leitner G.: Interactions between bacteria, immunity and therapy in the mammary gland. Proc. IDF Inter. Symp. Immunol. Ruminant Mammary Gland. Stresa, Italy 2000, s. 290-297.
• 31.Schmedt G. H., Tenhagen B. A., Kutzer P., Forderung D., Heuwieser W.: Do lactoferrin lysozyme and the lactoperoxidase-thiocyanate-hydrogen peroxide system cause negative microbiological results in mastitis secretion. Dt. Tierärztl. Wsehr. 2002, 109, 300-305.
• 32.Sears P. M., Guidry A. J., Belschner A.: Use of antigen-specific vaccines to enhance antibiotic treatment responses toward Staphylococcus aureus. Proc. 2nd Inter. Symp. Mastitis Milk Quality. Vancouver, BC, Canada 2001, s. 44-47.
• 33.Serieys F., Raguet Y., Goby L., Schmidt H., Friton G.: Comparative efficacy of local and systemic antibiotic treatment in lactating cows with clinical mastitis. J. Dairy Sci. 2005, 88, 93-99.
• 34.Sol J., Sampimon O. C., Barkema H. W., Schukken Y. H.: Factors associated with cure after therapy of clinical mastitis caused by Staphylococcus aureus. J. Dairy Sci. 2000, 83, 278-284.
• 35.Taponen S., Dredge K., Henriksson B., Pyyhtiä A. M., Suojala L., Junni R., Heinonen K., Pyörälä S.: Efficacy of intramammary treatment with procaine penicillin G vs. procaine penicillin G plus neomycin in bovine clinical mastitis caused by penicillin-susceptible, gram-positive bacteria a double blind field study. J. Vet. Pharmacol. Ther. 2003, 26, 193-198.
• 36.Timms L.: Field trial of extended pirlimycin therapy with or without vaccination for Staphylococcus aureus mastitis. Proc. 2nd Inter. Symp. Mastitis Milk Quality. Vancouver, BC, Canada 2001, s. 538-539.
• 37.Vaz A., Paterno M., Marca A.: Vaccination of lactating cows improves the efficacy of anti-Staphylococcus intramammary therapy. Med. Vet. Quebec 2004, 34, 169.
• 38.Wenz J. R., Barrington G. M., Garry F. B., McSweeney K. D., Dinsmore R. P., Goodell G., Callan R. J.: Bacteriemia associated with naturally occurring acute coliform mastitis in dairy cows. J. Am. Vet. Med. Assoc. 2001, 219, 976-981.
• 39.Wilson D. J., Sears F. M., Gonzalez R. N., Smith B. S., Schulte H. F., Bennett G. J., Das H. H., Johnson C. K.: Efficacy of florfenicol for treatment of clinical and subclinical bovine mastitis. Am. J. Vet. Res. 1966, 57, 526-528.